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Summary 
Human CD34 + hematopoietic progenitor cells,  stringently purified from the peripheral blood 
of 20 normal donors,  showed an impaired survival and clonogenic capacity after exposure to 
either heat-inactivated  human  immunodeficiency virus  (HIV)  1  (strain  IIIB) or cross-linked 
envelope gp120.  Cell cycle analysis,  performed at different times in serum-free liquid culture, 
showed an accumulation in G0/G1 in HIV-1- or gp120-treated cells and a progressive increase 
of cells  with  subdiploid  DNA  content,  characteristic  of apoptosis.  In blocking experiments 
with  anti-transforming growth  factor  (TGF)  [31  neutralizing  serum or TGF-[31  oligonucle- 
otides,  we  demonstrated  that  the  HIV-1-  or  gp120-mediated  suppression  of CD34  +  cell 
growth was almost entirely due to an upregulation of endogenous TGF-131 produced by puri- 
fied hematopoietic progenitors. Moreover, by using a sensitive assay on the CCL64 dell  line, 
increased levels of bioactive TGF-[31  were  recovered in  the  culture  supernatant  of HIV-1/ 
gp120-treated  CD34 +  cells.  Anti-TGF-[31  neutralizing  serum  or  TGF-~I  oligonucleotides 
were also  effective in inducing a significant increase of the plating efficiency of CD34 + cells, 
purified from the peripheral blood of three  HIV-l-seropositive individuals,  suggesting that a 
similar mechanism may be also  operative in vivo. The relevance of these findings to a better 
understanding of the pathogenesis of HIV-l-related cytopenias is discussed. 
A 
common  feature  of the  progression  toward  AIDS  is 
that,  besides  the  reduction  in  CD4 +  T  cell  count, 
other peripheral blood cytopenias such as anemia, granulo- 
cytopenia,  and  thrombocytopenia invariably take place  in 
up  to  80%  of HIV-l-seropositive subjects  (1).  The  he- 
matopoietic dysfunction in symptomatic HIV-l-seroposi- 
tive subjects is underscored by an impaired in vitro growth 
capacity of either  peripheral  blood  or  bone  marrow  he- 
matopoietic progenitor cells (2).  Significantly, CD34 + cells 
purified from the bone marrow of AIDS patients also show 
poor colony-forming ability (3-6). 
Although a variety of mechanisms have been claimed in 
the  pathogenesis  of peripheral blood  cytopenias  of AIDS 
patients (1), the role played by HIV-1 remains initially elu- 
sive. In fact, direct HIV-1 infection ofCD34 + hematopoi- 
etic progenitor cells isolated from HIV-l-seropositive car- 
riers has been reported only in a limited subset of cases and 
can  hardly  account  for the  functional  impairment of he- 
matopoiesis observed in these patients (3-9). Similarly, only 
a minority of purified CD34 + cells are susceptible to either 
productive or latent infection with HIV-1 in vitro (9-15). 
Therefore, the direct infection of hematopoietic stem/pro- 
genitor cells does not seem to be a leading cause for the ob- 
served pathophysiology, suggesting that mechanisms other 
than direct infection may be responsible for the AIDS-asso- 
ciated hematopoietic suppression. 
In this  context,  we  have previously shown  that  the  in 
vitro exposure to either lymphocytotropic strains of HIV-1 
(IIIB or  ICR-3)  or  cross-linked  gp120  significantly  im- 
paired  the  survival and  growth  of the  TF-1  CD34 §  he- 
matopoietic cell line as well as bone marrow CD34 + cells 
(16).  This suppressive effect appeared to be greatly depen- 
dent on the viral load,  but took place in the absence of a 
productive or latent infection and was likely mediated by 
specific interactions of envelope gp 120 with the CD4 anti- 
gen, expressed at low level on the surface of a subset of hu- 
man hematopoietic progenitor cells (17,  18). 
It was previously shown by single-cell cultures and limit- 
ing  dilution  analysis  that  early  hematopoietic  progenitor 
cells are able to produce autocrine TGF-131  (19, 20), which 
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the  quiescence  state  of  stem  cells  and  more  immature 
hematopoietic  progenitors.  Here  we  explore  whether  en- 
dogenous  production  of TGF-]31  could  take  part  in  the 
HIV-1/gp120  inhibitory effect  on  CD34 +  hematopoietic 
progenitors. To do this, we studied the effect ofanti-TGF- 
131  serum or TGF-181  antisense oligomers on the  survival 
and clonogenic capacity of CD34 +  cells, purified from the 
peripheral blood of healthy donors and HIV-l-seropositive 
carriers, in both serum-free suspension and senlisolid assays. 
Materials  and Methods 
Growth  Factors, Antibodies,  and  Oligodeoxynucleotides.  rlL-3 and 
stem  cell factor  (rSCF),  were  purchased  from  Genzyme Corp. 
(Cambridge, MA). Erythropoietin (rEp)  was kindly provided by 
Cilag (Milan, Italy).  Purified TGF-[31 was purchased from R&D 
Systems, Inc. (Minneapolis, MN). 
In neutralizing experiments,  rabbit anti-TGFd31  (tL&D  Sys- 
tems.  Inc.),  rabbit anti-IFN-er  (104 neutralizing units/ml; Bio- 
source, Camarillo, CA) and rabbit anti-TNF-o~ (Genzyme Corp.) 
polyclonal sera were  used.  In preliminary experiments, 20 Ixl of 
anti-TGF-[31 serum could completely neutralize 100 ng of TGF-[31. 
21mers corresponding to the antisense, sense, or missense se- 
quences flanking the translation initiation regions of the mRNA 
for TGF-I31 were  prepared  as described by Hatzfeld et al.  (19). 
The sequence of the phosphorothioate oligonucleotides are as fol- 
lows: TGF431 antisense, 5'-CCCGGAGGGCGGCATGGGGGA- 
3';  TGF-[31  sense,  5'-TCCCCCATGCCGCCCTCCGGG-Y; 
TGF-[31 missense, 5'-GGCGAGCGAGTGAGCGCGCGG-3'. 
Isolation q[ CD34 + Progenitor Cells  from Peripheral Blood.  Intbrmed 
consent for the study was obtained according to the Helsinki dec- 
laration  of  1975  from  20  healthy  donors  and  3  HIV-l-sero- 
positive  subjects.  Mononuclear  cells  were  isolated  from  leu- 
kapheresis  units  (healthy donors)  or 60  ml of peripheral  blood 
(HIV-l-seropositive donors)  by Ficoll-Paque (d  =  1.077  g/nil: 
Phamiacia,  Uppsala,  Sweden),  rinsed,  and  adherence-depleted 
overnight.  Nonadherent cells  were  collected and aliquoted at  a 
concentration of 25  ￿  106  cells/tube.  50  p.l  of the  following 
mAbs were added to each tube: anti-CD2, anti-CD3, anti-CD8, 
anti-CD11, anti-CD14, anti-CD19, anti-CD20 (Becton Dickin- 
son & Co., San Jose, CA) in the presence of 0.5% BSA (fraction 
V Chon; Sigma Chemical Co., St.  Louis, MO). After two wash- 
ings, 100  ￿  106 imnmnomagnetic beads, coated with anti-mouse 
IgG  (MPC  450  Dynabeads;  Dynal,  Oslo,  Norway)  were  then 
added to each tube to obtain an inmmnomagnetic bead/cell ratio 
of 10:1 in a final volume of 0.4 rrfl for 30 rain in ice, under con- 
tinuous agitation. Lineage-positive cells were removed by a mag- 
net (MPC 1 Dynabeads; Dynal) and the remaining cells were pel- 
leted  at  a  concentration  of  5  ￿  106  cells/tube.  After  these 
negative selections, CD34 + cells  were  isolated using a  magnetic 
cell  sorting  program  (Mini-MACS;  Miltenyi  Biotec,  Auburn, 
CA) and the CD34 isolation kit in accordance with the manufac- 
turer's reconmlendations. 
The  purity of CD34-selected  cells  was  determined tbr  each 
isolation by flow cytomet  W using a mAb that recognizes a sepa- 
t Abbreviations used in  this paper: BFU-E, burst-forming  unit, erythroid; 
BFU-meg, BFU-megakaD'ocyte; CFU-GM, colony-forming unit-granu- 
locyte macrophage; CFU-meg, CFU-megakaD'ocyte; Ep, eD'thropoietin; 
PB,  peripheral blood:  Pl,  propidium iodide;  R.T, reverse transcriptase; 
SCF, stem cell factor: TCID50, tissue culture infectious dose 50. 
rate epitope of the CD34 molecule (HPCA-2; Becton Dickinson 
& Co.) followed by a goat anti-mouse lgG directly conjugated to 
fluorescein (GAM-FITC). CD34 + cells  averaged N95-98%.  No 
differences in CD34 purity, were observed in HIV-l-seronegative 
and ~eropositive donors. 
The presence of proviral DNA in CD34 + cells  purified from 
HIV-l-seropositive subjects was exanfined by PCR, following a 
previously described procedure (7), with a sensitivity of 10 provi- 
ral copies in a background of 104 cells. Aliquots of 20,000 CD34 + 
cells  were  amplified with the HIV-1 gag-specific  primers SK38- 
SK39. PCR runs included several reactions containing all reagents 
except DNA as negative controls, as well as HIV-1 + controls rep- 
resented by H9 and Jurkat T  cell lines chronically infected with 
HIV-1. At the end of the amplification reaction, 25-btl aliquots of 
the amplified products were resolved in a 3% agarose gel. 
Virus Stock and Recombinant  Viral Proteins.  Vires stock was re- 
presented by the supernatant of H9 lymphoblastoid T  cells  cul- 
tured at  optimal cell density (0.5-1.5  X  106 cells/ml) arid har- 
vested 14 d after infection with HIV-1  (strain IIIB). It contained 
a reverse transcriptase (RT) activity of 1.5  X  106 cpm/ml with an 
infectivity of 3  X  106 TCID50 (tissue  culture infectious dose 50) 
equivalents for lymphocytes, determined as previously described 
(14).  1 nil of purified, high-titer stock of HIV-I was first heat in- 
activated of infectious virus at 59~  for 45 min, and then added 
to CD34- cells for 2 h at 37~  Control (mock-treated) cultures 
were run in parallel by challenging CD34 + cells with 1 nfl of the 
supematant of uninfected H9 lymphoblastoid T cells cultured un- 
der  optimal  conditions.  After  virus  adsorption,  the  cells  were 
plated in liquid or semisolid cultures. The absence of infectious 
virus after heat inactivation was checked by adding HIV-1 IIIB to 
permissive T  lymphoblastoid H9 and Jurkat T  cell lines or PHA- 
stimulated  PBMC.  In  some  experiments,  CD34 +  cells  were 
treated  with  heat-inactivated HIV-1  plus  increasing concentra- 
tions (1-100 ng/ml) of purified TGF-131. 
In experiments with  recombinant etw proteins,  several  doses 
(10 ng-10 lxg) ofbaculovirus-derived HIV-1 gp120  (ABT, Cam- 
bridge, MA)  were added to cells  for  1 h  at 4~  followed by 3(3 
min at  4~  with  20  ILl rabbit anti-gpl20  (ABT)  serum  before 
plating. To control for nonspecific protein effects,  we performed 
experiments  with  baculovirus-derived recombinant p24  (ABT) 
nmrine lgG,  hmnan lgG  followed by 20  ~I of rabbit anti-p24 
(ABT),  rabbit anti-mouse IgG, or rabbit anti-human lgG anti- 
sera,  respectively. Normal rabbit serum was also included as addi- 
tional control. 
Serum-free Suspemion  Cultures.  To  eliminate the  influence of 
TGF-[3I contained in serum or plasma (21),  purified CD34 + cells 
were  resuspended  in  serum-free  medium  (IMDM  containing 
10 -4  M  BSA-adsorbed  cholesterol  and  nucleosides,  10  p,g/ml 
each, 0.5% BSA,  10 ~g/ml insulin, 2% 21)0 p,g/ml iron-saturated 
transferrin, 5  ￿  10 -5 M  2-[3-ME)  containing IL-3  (0.4  ng/ml) 
and SCF (40 ng/ml). 50,000 cells/well were incubated in 48-well 
flat-bottom tissue culture plates  (Nunc,  1Loskilde,  Denmark)  in 
0.2 nil of medium at 37~  in a water-saturated atmosphere of 5% 
CO2  for  the  next  15  d.  Using trypan blue dye  exclusion,  the 
number of viable cells was determined over this 15-d period. 
To minimize the influence of possible endotoxin contamina- 
tions, all the experimental procedures were perfomled in endo- 
toxin-free plastic ware. According to the manufacturer's informa- 
tion,  the  levels  of  endotoxin  contamination  in  the  cytokine 
preparations were  <0.13  endotoxin U/ml by the Limulus assay 
(E-Toxate; Sigma Chemical Co.; limit of detection, 0.06 EU/ml). 
Cell Cycle  Analysis and  [3H]Thi, midine  Incorporation Assa),.  At 
different  time  points,  cells  were  harvested  from  liquid culture, 
100  HIV-1 gp120 Upregulates TGF-[31 Production by CD34 + Cells fixed in 70% ethanol for 1 h at 4~  and then incubated with 20 
btg/ml of RNase for 30 min at 37~  Nucleic DNA was stained 
with 50 ~g/ml propidium iodide (PI; Sigma Chemical Co.) and 
allowed to equilibrate for 10 min in the dark before being ana- 
lyzed as described  (22). Fluorescence analysis of individual nuclei 
was  performed  by  the  use  of  a  FACScar/g  flow  cytometer 
equipped with an argon-ion laser (488-nm wavelength, 100-mW 
light output) and lysis II software (Becton Dickinson & Co.). The 
fluorescence  intensity from cell nuclei stained with PI is propor- 
tional to the cellular DNA content. 
For the [3H]thymidine incorporation assay, cells were counted 
at  different  time  points  of liquid culture,  and  then  seeded  at 
50,000/100  ~1  in  96-well  flat  bottom  tissue  culture  plates 
(Nunc). 1 ~Ci [3H]thymidine (6.7 Ci/mmol; DuPont New En- 
gland Nuclear, Boston, MA) was added to each well for 4 h of in- 
cubation. Radioactivity incorporated into DNA was measured by 
liquid scintillation counting. 
Detection qf TGF-~ I mRNA.  Total RNA was  isolated  from 
-'~1  ￿  105 enriched CD34 § cells by using RNAzol B  (Biotecx 
Texas,  Houston, TX),  according to  the manufacturer's instruc- 
tions, and resuspended in 10  Ftl of diethylpyrocarbonate-treated 
water.  Reverse transcription was performed for 10 rain at room 
temperature and for 60 min at 42~  on 1 ~g of RNA (equivalent 
to  5  X  104 cells) in 20  ~tl of a reaction mixture containing 10 
mM Tris HCI (pH 8.3), 50 mM KCI, 5 mM MgC12, 0.l% gela- 
tin, 100 pM random hexamer primers,  20 U  of placental RNase 
inhibitor (Boehringer Mannheim, Postfach,  Germany), 100 U  of 
RT (Perkin-Elmer Cetus Instruments, Norwalk, CT), and 1 mM 
of dATP,  dCTP,  dGTP,  and dTTP.  Each  cDNA sample  was 
then used as template for the PCR assay. The PCR mixture con- 
tained 10 mM Tris HCI (pH 8.3), 50 mM KCI, 2.5 mM MgCI2, 
0.l%  gelatin,  100  pM  of TGF-[31  primers,  and 2.5  U  of Taq 
polymerase (Perkin-Elmer Cetus Instruments). The TGF-[31 primers 
5'-CAGAAATACAGCAACAATTCCTGC-3'  and 5'-TTGC- 
AGTGTGTTATCCGTGCTGTC-3'  were prepared  according 
to  Kekow et  al.  (23) and define a  186-bp fragment extending 
from § 1358 to +1544 in the TGFq31 transcript  (24). PCR reac- 
tion was performed in a 100-1xl vol for 35 cycles (denaturing 1' at 
94~  annealing 1' at 55~  and extension 1'30" at 72~  20 Ixl of 
the PCR products was then resolved  in a 3% agarose gel.  The 
positive  control was  a TGF-131 cDNA digested  with PstI (24), 
whereas the negative control was a TGF-[32 cDNA digested with 
BamH1  (25), each at 1,200 template copies. 
TGF-~31 Protein Determination.  Superuatants  were  collected 
from serum-free 3d CD34 + cell suspension cultures.  These sam- 
ples were tested  for TGF-13I activity after transient acidification: 
pH in the supernatants  was reduced to pH 2 by the addition of 5 
tool/liter HC1 for 2 h and then neutralized to pH 7 with 1.4 mol/ 
liter NaOH in 0.7 tool/liter Hepes.  Titers of TGF-I31  were ex- 
pressed in nanograms per milliliter based on a standard curve that 
was  generated with each  set  of assays by using purified human 
TGFd31 (R&D Systems, Inc.). The total amount of TGF-I31 in 
CD34 § cell culture supernatant was determined by antibody neu- 
tralization. The bioassay on CCL64 mink lung epithelial cells (26) 
was performed as described  previously (27). Briefly,  10  s CCL64 
cells/well were seeded  in 0.2  ml of serum-free medium in 96- 
well flat-bottom tissue  culture plates  (Nunc). Serial  concentra- 
tions of purified TGF-[31  or  CD34 +  cell  culture  superuatants 
were  added to  CCL64  cells in appropriate  dilutions in the  ab- 
sence or presence of 20 Ftl of anti-TGF-131 serum. Cultures were 
incubated at 37~  for 24 h, and 1 btCi [3H]thymidine  (DuPont) 
was added to each well during the final 4 h of incubation. Radio- 
activity was measured by liquid scintillation counting. 
Assay for Clonogenic Cells and Scoring Criteria.  Colony assays for 
erythroid  (BFU-E),  granulocyte/macrophage  (CFU-GM),  and 
megakaryocyte  (BFU-meg and CFU-meg) progenitors were per- 
formed in serum-free fibrin clot cultures as previously described 
(28). Briefly,  1,000 CD34 + cells were seeded in IMDM supple- 
mented with 300  ~g/ml iron saturated  transferrin,  3  mg BSA, 
280  ~g/ml  CaC12; 10 -4  M  BSA-adsorbed  cholesterol,  20  Ixg 
t-asparagine, 1.7  ￿  106 M insulin, nucleosides  (10 btg/ml each), 
0.1 ml of 0.2% (wt/vol) purified fibrinogen resuspended  in PBS, 
and 0.1 ml of 0.2 U/ml purified human thrombin (95%) in PBS. 
All  reagents,  except  fibrinogen (provided by Kabi AB,  Stock- 
holm, Sweden), were purchased from Sigma Chemical Co. 
For the  identification of megakaryocyte  aggregates,  after  12 
(CFU-meg) and 21  (BFU-meg) d  of culture, fibrin clots  were 
fixed  in situ  with methanol-acetone (1:3) for  20  min, washed 
with  PBS  and  double-distilled water,  air  dried,  and  stored  at 
-20~  until  immunofluorescence  staining  was  performed. 
Megakaryocyte  colonies were composed of cells intensively fluo- 
rescent to anti-CD41W (Becton Dickinson & Co.) mAb directed 
against  the  glycoprotein llb/Illa complex.  CFU-meg were  al- 
ways unifocal and composed of 3-50 megakaryocytic  cells/col- 
ony, whereas BFU-meg were mainly plurifocal  (from 2 to 7 foci 
of development) and usually composed of >50 cells/colony. 
Pure  erythroid and mixed granulocyte/macrophage colonies 
were identified in situ according to standard morphological crite- 
ria at the day of maximal growth (12 d). Whereas BFU-E were 
readily detectable  fbr the presence  of hemoglobin, for the identi- 
fication  of CFU-GM, fibrin clots  were  frxed  and stained with 
Wright-Giemsa. 
Statistical Analysis.  The mean of the values +  SD for different 
experiments are shown in the Figures and Tables. Significant dif- 
ferences between treatment groups were deterrmned by using the 
two-tailed Student's t test applied for unpaired data. 
Results and Discussion 
Purified peripheral blood (PB)  CD34 +  cells were  chal- 
lenged with  either  high  titers  of heat-inactivated HIV-1 
(IIIB strain) or cross-linked gp120, and then seeded in a se- 
rum-flee fibrin clot  semisolid assay.  We  tested  these  re- 
agents over a wide range of concentrations, and the results, 
shown  in Fig.  1,  are  those  obtained with  concentrations 
that  gave  the  most pronounced effects  on  colony forma- 
tion. 
The overall plating efficiency of the cells in control cul- 
tures containing optimal concentrations of IL-3, SCF, and 
Ep  was  only partially reduced  in the  presence  of HIV-1 
virions or viral glycoproteins. In fact,  the  difference with 
control cell cultures was statistically significant (p  <  0.05) 
only for BFU-meg (Fig. 1 A). On the other hand, cell cul- 
tures treated with HIV-1  or cross-linked gpl20 showed a 
substantial (p <  0.01) decrease in the size (number of cells/ 
colony) of all colonies except  CFU-meg that were  unaf- 
fected (Fig. 1 /3). Of note, such inhibitory activity could be 
completely reversed by pretreatment of HIV-1  or  gpl20 
with soluble CD4,  suggesting the  existence of specific in- 
teractions between envelope gp120  and the  CD4  antigen 
expressed at low level by CD34  §  hematopoietic progeni- 
tors (13,  17,  18). 
As a first step toward elucidating the mechanisms under- 
101  Zauli et al. Figure  1.  Inhibitory  activity  of  heat-inactivated  HIV-1  (3  ￿  106 
TCID50) and cross-linked gp120 (5 b~g/ml + 20 Ixl ofanti-gpl20 serum) 
on the colony number (A) and size of different types of  progenitors (/3) in 
semisolid cultures. Data are reported as mean --+ SD of five separate ex- 
periments performed in duplicate. 
lying the  inhibitory  effect  of HIV-1  virions  or  envelope 
gp120  on PB hematopoietic progenitors, a  serum-free liq- 
uid suspension assay was devised to monitor the survival of 
CD34 +  cells. Typically, 50,000  cells, in a  final volume  of 
0.5  ml, were added per well to  48-well flat-bottom tissue 
culture  plates  containing  SCF  (40  ng/ml)  plus  IL-3  (0.4 
ng/ml). As can be seen in Fig. 2 A, these culture conditions 
allowed  for  the  survival  and  minimal  proliferation  of 
CD34 +  cells during the next  15  d  at 37~  at which  time 
they plateaued at only a  three- to fourfold amplification of 
starting cells.  Of note,  >60%  of the  15-d  cell population 
was  still CD34 +.  At this  time point,  no  significant differ- 
ences in the phenotypic expression ofCD34 + antigen were 
observed between HIV-l-mock-treated and treated groups 
(data not shown).  In the presence of HIV-1  or cross-linked 
gp120, a significant (p <  0.01) inhibition of the total num- 
ber  of viable  cells  was  observed  from  days  6-9  onward. 
Consistently,  a  progressive  inhibition  of DNA  synthesis 
with lower levels of [3H]thymidine incorporation was seen 
in HIV-1/gp120-treated cultures from day 3  onward  (Fig. 
2/3). Analysis of the cell cycle performed by flow cytome- 
try  after  PI  staining  showed  that  >60%  of control  cells 
Figure 2.  CD34 + cells were allowed to grow in serum-free suspension 
cultures as described in Materials and Methods and total cell numbers (A) 
and thymidine incorporation (/3) were, determined at various time points. 
H1V-1 and gp120 were used at the same concentrations reported in the 
legend to Fig. 1. Data represent the mean -- SD of  four to six separate ex- 
periments perfomaed in duplicate. 
were in G0/G1  at any time point considered with a back- 
ground  (~<2%)  of subdiploid DNA  (Table  1).  HIV-1  or 
cross-linked gp120  induced  a  significant  accumulation  of 
cells in G0/G1  phases (80-90%)  with a progressive increase 
of subdiploid DNA  (up  to  10-11%),  which  is  considered 
characteristic ofapoptosis. An example of such experiments 
is reported in Fig. 3. 
We then set out to determine whether the inhibitory ef- 
fect  of HIV-1  glycoproteins  on  the  survival  and  clonal 
growth ofhematopoietic progenitors could be mediated by 
TGF-]31,  a  pleiotropic  cytokine  that  plays  an  important 
physiological role  in  the  negative  regulation  of hemato- 
poiesis  (21,  29).  Several  lines  of evidence  suggested  that 
TGF-131  could  be  the  mediator  of  the  HIV-1/gp120- 
induced inhibition. In fact,  (a)  an autocrine production  of 
TGF-131  by hematopoietic progenitor cells has been dem- 
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Different Time Points of Suspension Culture 
Cell cycle composition  Cells with 
subdiploid 
Sampling time  S  G2/M  G0/G1  DNA 
% of cells  % 
3d 
Control  23  8  69  2 
HIV-  1  11  4  85  6 
HIV-1 +  CD4  21  9  70  2 
Cross-linked gpl20  9  3  88  7 
Cross-linked p24  25  9  66  1 
6d 
Control  26  9  65  1 
HIV-1  7  3  91  9 
HIV-1 +  CD4  24  10  66  3 
Cross-linked gp120  7  3  90  10 
Cross-linked p24  28  10  62  2 
12d 
Control  29  9  62  2 
HIV-1  3  2  95  11 
HIV-I +  CD4  26  8  66  1 
Cross-linked gp120  4  3  93  12 
Cross-linked p24  26  10  64  3 
Data represent the means of three separate experiments performed in 
duplicate. Standard deviations were within 9% of the mean. 
onstrated and proposed as an important regulatory mecha- 
nism of quiescence  for stem and early hematopoietic  pro- 
genitor cells (19, 20); (b) TGF-[~I is known to decrease the 
total cell output in liquid culture by either arresting cell cy- 
cle  progression  or  inducing  apoptosis  of  hematopoietic 
progenitor cells (29-32); and (c) TGF-[M is also able to ac- 
celerate the differentiation of early erythroid progenitors by 
significantly reducing the time required for the majority of 
CD34 + cells to become differentiated  (33). All these prop- 
erties of TGF-[31 were compatible with our present exper- 
imental  findings  on the  inhibitory  activity  of HIV-1  and 
envelope gpl20. 
Therefore, in the next group of experiments, PB CD34 + 
cells were first challenged with heat-inactivated HIV-1  or 
gp120,  and then seeded in liquid suspension  culture with 
or without 20 p~l of rabbit anti-TGF-[M neutralizing serum 
or  control  anti-mouse  IgG,  anti-TNF-Ix,  or  anti-IFN-o~ 
sera  (Fig. 4).  After 12-15 d  of culture,  1.5-2-fold increase 
in  the  number  of viable  cells  was  noticed  in  control  cul- 
tures supplemented with anti-TGF-[~l  (Fig.  4 A).  Signifi- 
cantly,  an  even  greater  increase  (3-3.5-fold)  in  total  cell 
number was found in cultures challenged with HIV-1 (Fig. 
4  B)  or cross-linked  gp120  (Fig.  4  C)  in  the  presence  of 
anti-TGF-[31 serum. 
To  further  assess  the  role  of TGF-[~I  in  the  HIV-1- 
induced impairment ofhematopoietic progenitor cell growth, 
PB CD34 + cells  were plated under optimal growth condi- 
tions at low cell concentration in 35-mm Petri dishes in se- 
rum-free fibrin  clot semisolid assay.  Addition of 8  IxM of 
the antisense but not the sense or missense TGF-[31 signifi- 
candy (p <  0.01)  enhanced the size ofBFU-E, CFU-GM, 
and BFU-meg (Fig.  5).  Once again,  the stimulatory effect 
of antisense  TGF-[31  oligomers  was  greater  in  HIV-1- 
treated (Fig. 5 /3) or gp120-treated (Fig. 5  C) cultures than 
in  control  (Fig.  5  A)  cultures.  Moreover,  the  addition  of 
anti-TGF-[31 neutralizing serum yielded a similar enhance- 
ment (p <  0.01)  of colony formation as achieved with ad- 
dition of antisense  TGF-[~I. Single-cell cultures from two 
separate experiments gave similar results (data not shown). 
To provide an additional  and direct proof that TGF-[31 
was  produced  by purified  hematopoietic  progenitor  cells, 
TGF-[~I  ml<NA  was  analyzed  by  RT-PCR  in  CD34  + 
cells  (Fig. 6 A). Expression of TGF-[31 mRNA  was found 
in CD34 + cells  treated with either the culture supematant 
of uninfected  H9  cells  or heat-inactivated  HIV-1.  More- 
over, to demonstrate  that TGF-[~I  protein was released in 
the  culture  supernatant  by CD34  +  cells  and  acted  exter- 
nally to the cells,  a highly sensitive bioassay on the CCL64 
epithelial cell line was used (Fig. 6/3). This group of exper- 
iments showed that significantly (p <  0.01) higher amounts 
of bioactive TGF-[~I  were released in the serum-free  cul- 
ture  supernatant  by CD34  +  cells  3  d  after treatment  with 
heat-inactivated HIV-1 or cross-linked gp120 with respect 
to cells treated with the supernatant of uninfected H9 cells 
A  GecG1 
AI LIl' 
r 
~l~ttploid 
Figure 3.  Cell cycle analysis of 
CD34  +  cells treated with  H9 
uninfected cell culture supema- 
tant (A; control) and heat-inacti- 
vated HIV-1  (B)  after 12  d of 
suspension cultures as described 
in Materials and Methods. A rep- 
resentative of three separate ex- 
periments  is  shown, x  axis, PI 
fluorescence,  y  axis,  relative 
number of  cells. 
103  Zauli et al. Figure 4.  Enhancement of total CD34  + cell numbers  grown in serum- 
free  suspension  cultures  in  the  presence  of anti-TGF-[31  serum.  Cells 
were supplemented  with H9 uninfected  cell culture supernatant  (A; con- 
trol),  heat-inactivated  HIV-1  (B), or cross-linked  gp120  (C)  using  the 
same concentrations  reported  in the legend to Fig. 1. Data represent  the 
mean +  SD of four separate experiments performed in duplicate. 
or  cross-linked  p24.  The  addition  of soluble  CD4  com- 
pletely  blocked  the  biological  activity  of TGF-]31  recov- 
ered  in  HIV-l-treated  CD34 +  cells.  Interestingly,  a  sup- 
pressive  effect  on  the  colony  formation,  similar  to  that 
previously found in the presence of either HIV-1 virions or 
cross=linked gpl20  (Fig.  1 B), was also observed in CD34 + 
cell cultures  supplemented  with low concentrations  (1-10 
Figure 5.  Enhancement of colony size by different types of progenitors 
plated at low cell density  (10  3 cells/ml) in the presence of TGF-[31 anti- 
sense oligomers  or anti-TGF-[~l serum,  Cells were supplemented  with 
H9  uninfected  cell  culture  supernatant  (+t; control),  heat-inactivated 
HIV-I (B), or cross-linked gpI20 (C) using the same concentrations  re- 
ported in the legend to Fig. 1. Data are reported  as means  ~+ SD of five 
separate experiments performed in duplicate. 
ng/ml)  of purified  TGF-[31  (Fig.  7  A).  These  concentra- 
tions were comparable  to those found in the culture super- 
natant  of HIV-1/gp120-treated  CD34 +  cells.  Together, 
these data further suggest that minimal amounts  of endoge- 
nous TGF-~I  released by CD34 +  cells can account for the 
inhibitory activity of HIV- 1/gp 120. 
Since  elevated levels  of circulating  TGF-131  have  been 
documented in HW-1--seropositive subjects  (34),  and TGF- 
[31 is able to trigger its own production  (35),  we next eval- 
uated  the  effect of purified  TGF-[~I  in  combination  with 
104  HIV-1 gp120 Upregulates TGF-~I Production by CD34 + Cells Figure 6.  (A) TGF-[31 mRNA expression in CD34 + cells. (A) Lane M, 
molecular  weight markers;  lane  1,  TGF-[32  cDNA  (negative  control); 
lane  2,  TGF-~I  cDNA (positive control);  lane  3,  CD34 §  cells treated 
with H9 uninfected  cell culture  supematant;  lane  4, H20 (negative con- 
trol);  lane  5,  CD34 + cells treated  with heat-inactivated  HIV-1; lane  6, 
CD34 + cells treated with heat-inactivated  HIV-1 plus soluble CD4.  (B) 
Quantitative  evaluation of the amount of TGF-[31 released in culture su- 
pernatants by CD34 + cells 3 d after exposure  to H9 uninfected  cell cul- 
ture  supernatant  (control),  heat-inactivated  HIV-1,  cross-hnked  gp120, 
heat-inactivated  HIV-I plus soluble CD4, and  cross-linked  p24  used at 
the same concentrations  reported  in the legend to Fig. 1. A representative 
of three separate experiments  is shown. 
heat-inactivated  HIV-1  (Fig.  7  B),  Exposure  to  high  con- 
centrations  of TGF-[31  (100 ng/ml) plus HIV-1  resulted in 
an additive inhibitory effect on  CD34 +  cell colony forma- 
tion,  suggesting that  exogenous  TGF-J31  may also  partici- 
pate  in  the  upregulation  of endogenous  TGF-[31  in  he- 
matopoietic progenitors. 
Figure  7.  Suppressive  effect  of increasing  concentrations  of TGF-[31 
alone (A) or in combination  with heat-inactivated  HIV-1 (/3) on the col- 
ony size of different  types of progenitors  in semisolid cultures. Data  are 
reported as mean  +  SD of three  to five separate experiments  performed 
in duplicate. 
In a last group  of experiments,  we investigated the effect 
of the  addition  of antisense  TGF-[31  oligonucleotides  or 
anti-TGF-131  serum  to  CD34 +  cells purified  from  the  PB 
of three  HIV-l-seropositive  individuals,  whose  hemato- 
logic parameters  are  shown  in  Table  2.  Of note,  the pres- 
ence of HIV-1  infection in enriched CD34 +  cells was pre- 
liminarily  excluded  by  gag  DNA  PCR,  performed  as 
described previously (7).  A  substantial  increase in the num- 
Table 2.  Hematological  Features of HIV-1-seropositive Patients 
Patient  Sex  Pit  Hb  WBC  CD4  CD8  gag DNA in CD34 + cells 
X 109/liter  g/dl  ￿  106/liter  X 106/liter  X 106/liter 
1  M  76  13.0  4,250  128  497  negative 
2  M  96  11.5  5,100  89  715  negative 
3  F  107  10.6  3,900  113  863  negative 
Pit, platelets; Hb, hemoglobin; WBC, white blood cells; CD4, CD4  + T  cells; CD8, CD8 + T cells. 
105  Zauli et al. Figure 8.  Enhancement  of colony number (A) and size (B) by different 
types of progenitors in semisolid cultures, and total number of CD34  + 
cells (C) purified from three HIV-l~seropositive  subjects in suspension 
cultures in the presence of TGF-[31 antisense oligomers  or anti-TGF-[31 
serum. Data are reported as means of experiments  performed  in duplicate. 
ber of viable ceils was noticed in suspension liquid culture 
(Fig.  8 A, 4-5 fold increase after 12-15 d) as well as in the 
number  (Fig.  8  B)  and  size  (Fig.  8  C)  of colonies  in  the 
presence  of either  antisense  TGF-[31  oligonucleotides  or 
anti-TGF-[31 serum. 
Our  results  indicate  that  the  suppressive effect induced 
by  HIV-1/gp120  on  CD34 +  hematopoietic  progenitor 
cells  is mediated by an upregulation  of TGF-[31,  endoge- 
nously  produced  by  CD34 +  hematopoietic  progenitors. 
The current model of hematopoiesis is that stem and early 
106 
progenitor cells are recruited from quiescence by early-act- 
ing cytokines into a colony-stimulating responsive state that 
enables  subsequent  proliferation  and  differentiation  (36). 
The entry into  cell cycle, however, is regulated in a feed- 
back loop  fashion:  inhibitory  molecules,  such  as  TGF-[31, 
limit the cycling of stem cells and consequently dampen the 
proliferative stimulus  (21).  TGF-131  is also  a potent differ- 
entiation inducer of cycling progenitors, since it may pre- 
maturely  trigger  terminal  differentiation  in  primitive  he- 
matopoietic progenitor cells,  thereby reducing the  overall 
number of mature cells (33). 
An HIV-1/gp120 suppression ofhematopoiesis based on 
an indirect mechanism, such as an increased release of en- 
dogenous  TGF-[31,  may explain several findings  reported 
in the literature:  (a) the frequency of CD34 + cells (number 
of CD34+/bone marrow mononuclear cells)  is not signifi- 
cantly reduced until very late stages of HIV-1 disease  (3-9); 
(b) nevertheless, CD34 + cells challenged in vivo or in vitro 
with HIV-1 or viral products show, at least in some studies, 
an  impaired  colony-forming ability  (3-7,  12-16);  and  (c) 
no correlations are found between presence of viral infec- 
tion,  either  productive  or  latent,  and  impaired  colony 
growth of CD34 + hematopoietic progenitors purified from 
HIV-l-seropositive subjects (3-7, 9). 
Experimental evidence suggests that TGF-[31 acts on tar- 
get cells by arresting or delaying cells in G0/G1 of the cell 
cycle (30,  31),  as well as by inducing apoptosis (32).  Both 
of these  effects  were  observed  in  HIV-1/gpl20-treated 
CD34 + cells.  The activity of TGF-[31  is mediated, at least 
in part, by maintaining the retinoblastoma growth suppres- 
sor protein in an active underphosphorylated state (37,  38) 
through an inhibition of the synthesis of the cyclin-depen- 
dent  kinase  (and/or  its  associated cyclin)  that  phosphory- 
lates the retinoblastoma or a block of the formation of this 
cyclin-kinase complex (39).  TGF-[31  may also  inhibit cell 
cycling by down modulating the expression of growth fac- 
tor receptors (40). 
Remarkably, neither a productive nor latent infection was 
required  to  upregulate  endogenous  TGF-~I.  Therefore, 
defective  virions  and/or  free  glycoprotein  gp120,  which 
are produced in abundance  by infected cells  (41),  may be 
effective as infective virions in the induction  of this TGF- 
[31-mediated inhibitory effect. The mechanism(s) by which 
HIV-1  or free  gp120  upregulates  the  production  and  re- 
lease of TGF-[31 remains to be fully elucidated. Analogous 
to mature myeloid cells  (42,  43), purified CD34 + hemato- 
poietic progenitor cells also constitutively express TGF-[31 
mRNA. However, due to the low number ofCD34 + cells 
achievable  from  each  sample,  the  presence  of TGF-[31 
mRNA could only be evaluated by ILT-PCR. This analy- 
sis  did  not  show  any significant  quantitative  difference  in 
the  levels of TGF-[31  mlLNA between  cells  treated with 
the supernatant of H9 uninfected cultures and cells treated 
with heat-inactivated HIV-1. Clearly, it will be important 
to determine whether gpl20 affects the stability ofmRNAs 
or the translation of TGF-[31  in CD34 + cells,  as proposed 
for mature monocytes/macrophages. 
Finally,  our data indicate  that  the  influence  of endoge- 
HIV-1 gp120 Upregulates TGF-[31 Production by CD34 + Cells nous TGF-131 on hematopoietic progenitors could be po- 
tentiated  by  combination with  inhibitory cytokines,  in- 
cluding exogenous TGF-[31,  produced  by  infected bone 
marrow and PB accessory cells in response to HIV-1 infec- 
tion or exposure to recombinant proteins (15, 23, 27, 42-44). 
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